Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Et forsøg for at lære, hvor effektivt og sikkert Odronextamab er sammenlignet med standardbehandling for voksne deltagere med tidligere behandlet aggressivt B-celle non-Hodgkin lymfom (OLYMPIA-4)

13. november 2026 opdateret af: Regeneron Pharmaceuticals

Et fase 3, randomiseret, åbent label-studie, der evaluerer effektiviteten og sikkerheden af ​​Odronextamab (REGN1979), et anti-CD20 x anti-CD3 bispecifikt antistof, versus standardbehandlingsterapi hos deltagere med recidiverende/refraktært aggressivt B-celle non-Hodgkin lymfom (OLYMPIA-4)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The aim of the study is to see how safe, tolerable and effective the study drug is when given alone.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug versus Standard of Care (SOC)
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drug (which could make the study drug less effective or could lead to side effects)
  • Comparing the impact from the study drug versus SOC on quality-of-life and ability to complete routine daily activities

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

216

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Córdoba, Argentina, X5000JHQ
        • Sanatorio Allende
      • Córdoba, Argentina, X5016KEH
        • Hospital Privado Universitario de Cordoba
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1118
        • Hospital Aleman
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1426
        • Instituto Alexander Fleming
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1280
        • Hospital Britanico de Buenos Aires
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1114AAN
        • Fundaleu - Fundacion Para Combatir La Leucemia
      • Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1199ABB
        • Hospital Italiano de Buenos Aires
      • La Plata, Buenos Aires, Argentina, B1900AUR
        • Hospital Italiano de La Plata
      • San Juan Bautista, Buenos Aires, Argentina, B1888AAE
        • Hospital Alta Complejidad El Cruce
    • Queensland
      • Woolloongabba, Queensland, Australien, 4102
        • Princess Alexandra Hospital
    • Victoria
      • Heidelberg, Victoria, Australien, 3084
        • Olivia Newton John Cancer Wellness & Research Centre
      • Rio de Janeiro, Brasilien, 20231050
        • Instituto Nacional de Cancer Jose Alencar Gomes da Silva
      • São Paulo, Brasilien, 08270-070
        • Casa de Saude Santa Marcelina
      • São Paulo, Brasilien, 01321000
        • A Beneficencia Portuguesa de Sao Paulo, Oncology House
      • São Paulo, Brasilien, 05403-000
        • Hospital das Clinicas, Faculty of Medicine, University of Sao Paulo
      • São Paulo, Brasilien, 01308-050
        • Hospital Sirio Libanes
      • São Paulo, Brasilien, 04501-000
        • Instituto D'Or De Pesquisa e Ensino
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 41950-640
        • Ensino e Terapia de Inovacao Clinica Amo (Etica)
      • Salvador, Estado de Bahia, Brasilien, 40285-000
        • Hospital Sao Rafael
      • Salvador, Estado de Bahia, Brasilien, 40050-410
        • Hospital Santa Izabel - Santa Casa de Misericordia da Bahia
    • Federal District
      • Brasília, Federal District, Brasilien, 70200-730
        • Hospital Sirio Libanes Brasilia
    • Paraná
      • Cascavel, Paraná, Brasilien, 85806-300
        • Uopeccan Hospital do Cancer de Cascavel
      • Curitiba, Paraná, Brasilien, 81520-060
        • Hospital Erasto Gaertner
    • Rio Grande do Sul
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90035-903
        • Hospital de Clinicas de Porto Alegre
      • Porto Alegre, Rio Grande do Sul, Brasilien, 90110-270
        • Centro Gaucho Integrado
    • São Paulo
      • Jaú, São Paulo, Brasilien, 17210-080
        • Amaral Carvalho Hospital
    • Santiago Metropolitan
      • Santiago, Santiago Metropolitan, Chile, 7500921
        • Fundacion Arturo Lopez Perez
      • Santiago, Santiago Metropolitan, Chile, 7650620
        • Clinica Alemana de Santiago
    • Antioquia
      • Medellín, Antioquia, Colombia, 050034
        • Hospital Pablo Tobon Uribe
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombia, 760042
        • Clinica Imbanaco
    • Johor
      • Johor Bahru, Johor, Malaysia, 80100
        • Hospital Sultanah Aminah Jhor Bahru
    • Kuala Lumpur
      • Kuala Lumpur, Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre
    • Sabah
      • Kota Kinabalu, Sabah, Malaysia, 88586
        • Hospital Queen Elizabeth
    • Selangor
      • Kuala Lumpur, Selangor, Malaysia, 68000
        • Hospital Ampang
      • Subang Jaya, Selangor, Malaysia, 47500
        • Subang Jaya Medical Center
    • Bucharest
      • Bucharest, Bucharest, Rumænien, 030141
        • Coltea Clinical Hospital
    • Cluj
      • Cluj-Napoca, Cluj, Rumænien, 400015
        • Ion Chiricuta Oncology Institute
      • Singapore, Singapore, 119074
        • National University Hospital Singapore
      • Madrid, Spanien, 28034
        • Hospital Universitario Ramon y Cajal
      • Pamplona, Spanien, 31008
        • Clinica Universidad de Navarra- Pamplona
      • Valencia, Spanien, 46009
        • Instituto Valenciano de Oncologia
    • Balearic Islands
      • Palma, Balearic Islands, Spanien, 07120
        • Hospital Universitari Son Espases
      • Busan, Sydkorea, 49201
        • Dong-A University Hospital
      • Busan, Sydkorea, 49241
        • Pusan National University Hospital
      • Daegu, Sydkorea, 42601
        • Keimyung University Dongsan Hospital
      • Seoul, Sydkorea, 05505
        • Asan Medical Center
      • Seoul, Sydkorea, 07345
        • Yeouido St. Marys Hospital
      • Seoul, Sydkorea, 06591
        • Seoul St Marys Hospital
      • Ulsan, Sydkorea, 44033
        • Ulsan University Hospital
    • Gyeonggi-do
      • Gyeonggi-do, Gyeonggi-do, Sydkorea, 10408
        • National Cancer Center
      • Suwon, Gyeonggi-do, Sydkorea, 16247
        • St. Vincent Hospital - The Catholic University of Korea
    • Gyeongsangnam-do
      • Yangsan, Gyeongsangnam-do, Sydkorea, 50612
        • Pusan National University Yangsan Hospital
    • Jeollabuk-do
      • Jeonju, Jeollabuk-do, Sydkorea, 54907
        • Jeonbuk National University Hospital
    • Namdong-Gu
      • Incheon, Namdong-Gu, Sydkorea, 21565
        • Gachon University Gil Medical Center
      • Changhua, Taiwan, 500-06
        • Changhua Christian Hospital
      • Changhua, Taiwan, 50008
        • Show Chwan Memorial Hospital
      • Kaohsiung City, Taiwan, 80756
        • Kaohsiung Medical University Hospital
      • Kaohsiung City, Taiwan, 83301
        • Chang Gung Memorial Hospital Kaohsiung
      • Taichung, Taiwan, 40705
        • Taichung General Veterans Hospital
      • Tainan, Taiwan, 704
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11490
        • Tri-Service General Hospital
    • Hunan Province
      • Taoyuan, Hunan Province, Taiwan, 33305
        • Chang Gung Memorial Hospital - Linkou Branch
      • Bangkok, Thailand, 10330
        • Chulalongkorn University
      • Bangkok, Thailand, 10700
        • Sriraj Hospital
      • Chiang Mai, Thailand, 50200
        • Chiang Mai University
      • Khon Kaen, Thailand, 40002
        • Khon Kaen University
      • Ankara, Tyrkiet (Türkiye), 06100
        • Sbu Dr.A.Y. Ankara Onkoloji Suam
      • Istanbul, Tyrkiet (Türkiye), 34365
        • VKV American Hopital
      • Istanbul, Tyrkiet (Türkiye), 34418
        • Istanbul University
      • Izmir, Tyrkiet (Türkiye), 35100
        • Ege University
      • Sakarya, Tyrkiet (Türkiye), 54290
        • Sakarya University Medical Faculty
      • Samsun, Tyrkiet (Türkiye), 55270
        • Ondokuz Mayıs University
      • Zonguldak, Tyrkiet (Türkiye), 67600
        • Zonguldak Bulent Ecevit University
    • Ankara
      • Mamak, Ankara, Tyrkiet (Türkiye), 06620
        • Ankara University Faculty of Medicine
    • Central Anatolia
      • Ankara, Central Anatolia, Tyrkiet (Türkiye), 06100
        • Gazi University
    • Mersin
      • Mezitli, Mersin, Tyrkiet (Türkiye), 33200
        • VM Medical Park Mersin Hospital
    • Suleymanpasa
      • Tekirdağ, Suleymanpasa, Tyrkiet (Türkiye), 59100
        • Tekirdag Namik Kemal University Hospital
      • Budapest, Ungarn, 1088
        • Semmelweis University
    • Baranya
      • Pécs, Baranya, Ungarn, 7624
        • University of Pecs
    • Hajdú-Bihar
      • Debrecen, Hajdú-Bihar, Ungarn, 4032
        • Debreceni Egyetem

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Key Inclusion Criteria:

  1. Histologically proven aggressive B-NHL, as described in the protocol. Availability of tumor tissue for submission to central laboratory is required for study enrollment. Archival tumor tissue for histological assessment prior to enrollment is allowed
  2. Have primary refractory or relapse 12 months or less (≤) from initiation of frontline therapy Only participants who received 1 prior line of therapy containing an anti-Cluster of Differentiation 20 (CD20) antibody and anthracycline are allowed for enrollment
  3. Have measurable disease with at least one nodal lesion with longer diameter (LDi) greater than 1.5 cm or at least one extranodal lesion with LDi greater than 1.0 cm, documented by diagnostic imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
  4. Intent to proceed to autologous stem cell transplant (ASCT), as described in the protocol
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  6. Adequate hematologic and organ function.

Key Exclusion Criteria:

  1. Primary central nervous system (CNS) lymphoma or known involvement by non-primary CNS NHL, as described in the protocol
  2. History of or current relevant CNS pathology, as described in the protocol
  3. A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer, cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated
  4. Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol
  5. Wash-out period from prior anti-lymphoma treatments and infections, as described in the protocol
  6. Allergy/hypersensitivity to study drug, or excipients.

NOTE: Other protocol defined inclusion / exclusion criteria apply

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Odronextamab

Participants will receive odronextamab monotherapy.

Administered by intravenous (IV) infusion

Andre navne:
  • R1979
Aktiv komparator: Standard Of Care

Participants will receive salvage therapy (ifosfamide, carboplatin, etoposide ± rituximab [ICE ± R], or dexamethasone, cisplatin, cytarabine ± rituximab [DHAP ± R], or gemcitabine, dexamethasone, cisplatin ± rituximab [GDP ± R]) and continue with autologous stem cell transplant (ASCT) following a complete response (CR)/partial response (PR).

Administered by IV infusion, as part of the ICE ± R salvage therapy

Andre navne:
  • Ifex

Administered by IV infusion, as part of the ICE ± R salvage therapy

Andre navne:
  • Paraplatin

Administered by IV infusion, as part of the ICE ± R salvage therapy

Andre navne:
  • Etopophos

Administered by IV infusion, as part of the ICE ± R, or DHAP ± R, or GDP ± R salvage therapy.

Andre navne:
  • Rituxan

Administered by IV, or orally (PO) as part of the DHAP ± R, or GDP ± R salvage therapy.

Andre navne:
  • Dekadron

Administered by IV infusion, as part of the DHAP ± R or GDP +/-R salvage therapy.

Andre navne:
  • Platinol

Administered by IV infusion, as part of the DHAP ± R salvage therapy.

Andre navne:
  • Cytosar-U

Administered by IV infusion, as part of the GDP ± R salvage therapy.

Andre navne:
  • Gemzar

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
Event-Free Survival (EFS) as assessed by independent central review (ICR)
Tidsramme: Assessed up to 3 years
Assessed up to 3 years

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
EFS vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
Vurderet op til 3 år
PFS vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
Vurderet op til 3 år
BOR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 6 måneder
Vurderet op til 6 måneder
CR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 6 måneder
Vurderet op til 6 måneder
DOR vurderet af lokal efterforsker
Tidsramme: Vurderet op til 3 år
Vurderet op til 3 år
Sværhedsgraden af ​​TEAE'er
Tidsramme: Vurderet op til 1 år
Vurderet op til 1 år
Odronextamab-koncentrationer i serum
Tidsramme: Vurderet op til 6 måneder
Vurderet op til 6 måneder
Responsens varighed (DOR) vurderet af ICR
Tidsramme: Vurderet op til 3 år
Vurderet op til 3 år
Progression Free Survival (PFS) as assessed by ICR
Tidsramme: Assessed up to 3 years
Assessed up to 3 years
Best Overall Response (BOR) as assessed by ICR
Tidsramme: Assessed up to 6 months
Assessed up to 6 months
Overall Survival (OS)
Tidsramme: Assessed up to 3 years
Assessed up to 3 years
Overall change in physical functioning as measured by scores of the physical function scale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC-QLQ-C30)
Tidsramme: Assessed up to 3 years

The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a global health status (GHS)/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Assessed up to 3 years
Complete Response (CR) as assessed by ICR
Tidsramme: Assessed up to 6 months
Assessed up to 6 months
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Assessed up to 1 year
Assessed up to 1 year
Occurrence of Anti-Drug Antibodies (ADAs) to odronextamab
Tidsramme: Assessed up to 6 months
Assessed up to 6 months
Magnitude of ADAs to odronextamab
Tidsramme: Assessed up to 6 months
Assessed up to 6 months
Measurable Residual Disease (MRD) status
Tidsramme: Assessed up to 6 months
Assessed up to 6 months
Overall change in Patient-Reported Outcomes (PROs), as measured by scores of the EORTCQLQ- C30
Tidsramme: Assessed up to 3 years

The EORTC QLQ-C30 includes 5 functional scales (physical, role, cognitive, emotional and social functioning), 3 symptom scales (fatigue, pain and nausea/vomiting), a GHS/QoL scale, and six single items (constipation, diarrhea, insomnia, shortness of breath, appetite loss and financial difficulties). For the functioning scales and global health status / QoL, scores range from 1 = "very poor" to 7 = "excellent" with higher scores indicate better functioning; for the symptom scales, scores range from 1 = "not at all" to 4 = "very much" higher scores indicate higher symptom burden.

Assessed up to 3 years
Overall change in PROs, as measured by scores of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-LymS)
Tidsramme: Assessed up to 3 years

The FACT-Lym lymphoma subscale (LymS) includes 15 items to assess NHL-related symptoms and concerns. All questions are answered on a 5-point scale ranging from "not at all" (0) to "very much" (4). Higher scores are associated with a worse quality of life.

Assessed up to 3 years
Overall change in PROs, as measured by scores of the EuroQol-5 Dimension-5 Level Scale (EQ-5D-5L)
Tidsramme: Assessed up to 3 years

The EQ-5D-5L consists of the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: "no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems". The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labeled "Best imaginable health state" and "Worst imaginable health state".

Assessed up to 3 years
Overall change in score of the Global Population item 5 (GP5) of the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire
Tidsramme: Assessed up to 3 years

A single item GP5 of the validated FACT-G questionnaire will be used to assess from the participant perspective the overall impact of treatment side-effect. The question item is on a 5-point scale ranging from "not at all" (0) to "very much" (4).

Assessed up to 3 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. februar 2024

Primær færdiggørelse (Anslået)

29. maj 2028

Studieafslutning (Anslået)

29. maj 2028

Datoer for studieregistrering

Først indsendt

29. december 2023

Først indsendt, der opfyldte QC-kriterier

18. januar 2024

Først opslået (Faktiske)

30. januar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

13. november 2026

Sidst verificeret

1. oktober 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • R1979-HM-2299
  • 2022-502783-21-00 (Ctis)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD-delingstidsramme

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD-delingsadgangskriterier

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • ANALYTIC_CODE
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .